Display Settings:

Format

Send to:

Choose Destination

    Blood Coagul Fibrinolysis. 2007 Oct;18(7):595-8.

    Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients.

    Zangari M, Barlogie B, Cavallo F, Bolejack V, Fink L, Tricot G.

    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA. zangarimaurizio@uams.edu

    Venous thromboembolism (VTE) is a cancer complication associated with poor survival. We have analyzed the prognostic impact of the development of a thrombotic episode in newly diagnosed multiple myeloma patients who received chemotherapy either with or without thalidomide on our Total Therapy 2 protocol. Of 668 patients enrolled, 155 developed VTE complication during treatment. The overall and event-free survival of patients who experienced VTE was not inferior. Of interest, we observed that patients who received intensive chemotherapy without thalidomide but developed a thrombosis experienced a significantly longer event-free survival compared with those without VTE (P = 0.02). Our observation suggests a possible beneficial effect of anticoagulation on survival in patients treated for myeloma.

    PMID: 17890944 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Patient drug information

    • Thalidomide (Thalomid®)

      Thalidomide is used along with dexamethasone to treat multiple myeloma in people who have been recently found to have this disease. It is also used alone or with other medications to treat and prevent skin symptoms of er...